Get the Stockscreener App
34.35
1.24%
-0.43
After Hours:
34.05
-0.30
-0.87%
Liquidia Corp stock is traded at $34.35, with a volume of 4.24M.
It is down -1.24% in the last 24 hours and down -49.82% over the past month.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.
See More
Previous Close:
$34.78
Open:
$34.78
24h Volume:
4.24M
Relative Volume:
0.58
Market Cap:
$3.07B
Revenue:
$288.07M
Net Income/Loss:
$22.31M
P/E Ratio:
242.58
EPS:
0.1416
Net Cash Flow:
$41.15M
1W Performance:
+25.46%
1M Performance:
-49.82%
6M Performance:
-17.03%
1Y Performance:
+48.19%
1-Day Range:
$33.33
$34.90
1-Week Range:
$26.13
$38.64
52-Week Range:
$21.94
$93.61
Liquidia Corp Stock (LQDA) Company Profile
Name
Liquidia Corp
Sector
Phone
919.328.4400
Address
419 DAVIS DRIVE, SUITE 100, MORRISVILLE, NC
Compare LQDA vs TAK, TEVA, HLN, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LQDA
Liquidia Corp
|
34.35 | 3.07B | 288.07M | 22.31M | 41.15M | 0.1416 |
TAK
Takeda Pharmaceutical Co Adr
|
19.67 | 62.84B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
41.50 | 48.40B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
10.13 | 44.55B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
79.38 | 32.80B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
533.12 | 22.87B | 3.17B | 1.29B | 1.01B | 27.09 |
Liquidia Corp Stock (LQDA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-14-26 | Upgrade | BTIG Research | Neutral → Buy |
| Oct-02-26 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Oct-01-26 | Downgrade | BTIG Research | Buy → Neutral |
| Oct-01-26 | Downgrade | Raymond James | Strong Buy → Outperform |
| Jun-29-26 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-20-25 | Initiated | Wells Fargo | Overweight |
| Aug-15-25 | Resumed | Jefferies | Buy |
| May-19-25 | Downgrade | Oppenheimer | Perform → Underperform |
| Dec-20-24 | Initiated | Wells Fargo | Overweight |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Aug-19-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-16-24 | Initiated | Raymond James | Outperform |
| Jun-25-24 | Initiated | Oppenheimer | Perform |
| Jan-05-24 | Reiterated | Needham | Buy |
| Sep-19-22 | Resumed | Wedbush | Underperform |
| Sep-01-22 | Downgrade | Wedbush | Neutral → Underperform |
| Jul-22-22 | Initiated | Ladenburg Thalmann | Buy |
| May-31-22 | Initiated | BTIG Research | Buy |
| May-26-22 | Initiated | BofA Securities | Buy |
| Dec-04-20 | Initiated | H.C. Wainwright | Buy |
| Nov-20-20 | Downgrade | Wedbush | Outperform → Neutral |
| Nov-08-18 | Resumed | Jefferies | Buy |
| Sep-05-18 | Initiated | Wedbush | Outperform |
| Aug-20-18 | Initiated | Jefferies | Buy |
| Aug-20-18 | Initiated | Needham | Buy |
View All
Liquidia Corp Stock (LQDA) Latest News
LQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia Label - Zacks Investment Research
Liquidia CBO Jason Adair sells $207,932 in shares after vesting - Investing.com
Liquidia Corp general counsel Schundler sells $389,948 of stock - Investing.com
Liquidia CCO Scott Moomaw sells $252,418 in company stock By Investing.com - Investing.com India
To cover stock-award taxes, Liquidia (LQDA) general counsel sells 13,692 shares at $28.48 each. - Stock Titan
Scott Moomaw Disposes 8,863 Shares of Liquidia Corp (LQDA) Following PSU Vesting on October 12, 2026 - Kalkine Media
Liquidia Corp's Rajeev Saggar Converts PSUs and Sells 9,218 Shares on October 12, 2026 - Kalkine Media
Liquidia Corp CBO Jason Adair Sells 7,301 Shares at $28.48 Following RSU and PSU Vesting in October 2026 - Kalkine Media
To cover stock-award taxes, Liquidia (LQDA) CFO and COO Kaseta sold 18,938 shares at $28.48 each. - Stock Titan
A tax-related sale at Liquidia (LQDA) totals 1,101 shares at $28.48 each. - Stock Titan
To cover stock-award taxes, Liquidia (LQDA) CEO Roger Jeffs sold 32,744 shares. - Stock Titan
To cover award taxes, Dana Boyle sells 5,892 Liquidia (LQDA) shares at $28.48 each. - Stock Titan
Stephen M. Bloch Sells 235,477 Liquidia Shares via Canaan VIII L.P. at $27.13 Average Price - Kalkine Media
Liquidia director Stephen Bloch sells $6.39m in shares - Investing.com
LIQUIDIA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Liquidia Corporation on Behalf of Liquidia Stockholders and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
Liquidia Stock Plunges 57% on UTHR Patent Litigation Setback - Zacks Investment Research
UTHR Prevails in LQDA's Yutrepia Patent Dispute, Stock Up Nearly 13% - Zacks Investment Research
Liquidia Corporation (LQDA) Stock Price & News - Syfe
Option exercises and share sales by Liquidia (NASDAQ: LQDA) director - Stock Titan
Liquidia (NASDAQ:LQDA) Rating Lowered to "Hold" at Wall Street Zen - MarketBeat
Director at Liquidia (NASDAQ: LQDA) plans $619K stock sale - Stock Titan
LQDA Loses 13.9% in a Month: Should Investors Avoid the Stock Now? - Yahoo Finance
Liquidia Corporation $LQDA Holdings Decreased by Opaleye Management Inc. - MarketBeat
Can a Potential Label Expansion of Yutrepia Boost LQDA's Portfolio? - Yahoo Finance
What Could Put Liquidia (NASDAQ:LQDA) On A New Path? - Kalkine Media
LQDA - Finviz
LQDA - Finviz
LIQUIDIA CORP (NASDAQ:LQDA) Fits the Affordable Growth Screen - ChartMill
Liquidia at Wells Fargo 21st annual healthcare conference: growth and pipeline - Investing.com India
Liquidia at Wells Fargo 21st annual healthcare conference: growth and pipeline - Investing.com
Liquidia at Wells Fargo 21st annual healthcare conference: growth and pipeline - Investing.com UK
Wellington Management Group LLP Sells 22,925 Shares of Liquidia Corporation $LQDA - MarketBeat
Liquidia Corp Stock Intrinsic Values - GuruFocus
Does FDA Fast Track For YUTREPIA In SSc Raynaud’s Change The Bull Case For Liquidia (LQDA)? - Yahoo Finance
Is Liquidia (LQDA) Still Undervalued As Fast Track News Tests Its Valuation? - Yahoo Finance
Liquidia (LQDA) Stock Looks Stretched On Earnings But Reasonable On Broader Checks - Yahoo Finance
Liquidia Corp CHRO Sarah Krepp Sells 274 Shares Under Pre-Set 10b5-1 Trading Plan - kalkinemedia.com
Liquidia Corp (NASDAQ: LQDA) Secures FDA Fast Track for YUTREPIA Targeting Raynaud’s Phenomenon in Up to 90% of Systemic Sclerosis Patients - Kalkine Media
How Does Liquidia Corporation's (NASDAQ:LQDA) PRINT Platform Actually Work? - Kalkine Media
Why Is Liquidia Stock Gaining Thursday?Liquidia (NASDAQ:LQDA) - Benzinga
Liquidia Corporation’s (LQDA) Yutrepia Launch Continues to Outpace the Expectations - Yahoo Finance
LQDA Looks 75.0% Undervalued on GF Value™ - GuruFocus
Liquidia’s YUTREPIA Receives FDA Fast Track Designation for Systemic Sclerosis-Associated Raynaud’s Phenomenon - Quiver Quantitative
Liquidia Gets FDA Fast Track for YUTREPIA Raynaud's | LQDA Stock News - Stock Titan
Liquidia Corporation $LQDA Shares Sold by Pale Fire Capital SE - MarketBeat
Liquidia Corporation (NASDAQ:LQDA) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
Liquidia Corp (LQDA) Shares Surge 4.1% -- What GF Score of 70 Te - GuruFocus
Liquidia to Present Posters at the European Respiratory Society (ERS) 2026 Congress - finance.yahoo.com
Two lung-disease studies will be presented in Barcelona - Stock Titan
Liquidia Corporation to Participate in Wells Fargo Annual Healthcare Conference - The Manila Times
Liquidia Corp Stock (LQDA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Liquidia Corp Stock (LQDA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Adair Jason | Chief Business Officer |
Oct 12 '26 |
Sale |
28.48 |
7,301 |
207,932 |
177,957 |
| Khindri Sanjeev | Chief Development Officer |
Oct 12 '26 |
Sale |
28.48 |
1,101 |
31,356 |
64,846 |
| Kaseta Michael | CFO and COO |
Oct 12 '26 |
Sale |
28.48 |
18,938 |
539,354 |
340,148 |
| JEFFS ROGER | Chief Executive Officer |
Oct 12 '26 |
Sale |
28.48 |
32,744 |
932,549 |
1,125,848 |
| Boyle Dana | Chief Accounting Officer |
Oct 12 '26 |
Sale |
28.48 |
5,892 |
167,804 |
165,609 |
| Saggar Rajeev | Chief Medical Officer |
Oct 12 '26 |
Sale |
28.48 |
9,218 |
262,529 |
126,368 |
| Moomaw Scott | Chief Commercial Officer |
Oct 12 '26 |
Sale |
28.48 |
8,863 |
252,418 |
181,487 |
| Krepp Sarah | Chief Human Resource Officer |
Oct 12 '26 |
Sale |
28.48 |
5,245 |
149,378 |
115,241 |
| Bloch Stephen M | Director |
Oct 05 '26 |
Sale |
27.13 |
235,477 |
6,387,596 |
0 |
| SINGH RAMAN | Director |
Sep 14 '26 |
Option Exercise |
9.31 |
8,468 |
78,799 |
53,105 |
4.74%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):